The range of vitronectin in neuroblastoma patients range from 52.4 to 870 μg mL−1, with a suggested cut-off of 361 μg mL−1 as this is when patients over the age of 18 months had worse prognosis. This evidence concerns the gene VTN and neuroblastoma.